<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC1873980/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Different effects of itraconazole on the pharmacokinetics of
fluvastatin and lovastatin</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC1873980/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin" />
<meta name="citation_authors" content=
"K T Kivistö, T Kantola, P J Neuvonen" />
<meta name="citation_date" content="July 1998" />
<meta name="citation_issue" content="1" />
<meta name="citation_volume" content="46" />
<meta name="citation_firstpage" content="49" />
<meta name="citation_doi" content=
"10.1046/j.1365-2125.1998.00034.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC1873980/?report=abstract" />
<meta name="citation_pmid" content="9690949" />
<meta name="DC.Title" content=
"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="K T Kivistö" />
<meta name="DC.Contributor" content="T Kantola" />
<meta name="DC.Contributor" content="P J Neuvonen" />
<meta name="DC.Date" content="1998 Jul" />
<meta name="DC.Identifier" content=
"10.1046/j.1365-2125.1998.00034.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"The effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin, two inhibitors of HMG-CoA reductase with different pharmacokinetic properties, were studied.Two separate randomized, placebo-controlled, cross-over studies, each involving ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1873980/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC1873980/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC1873980/pdf/bcp0046-0049.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FB6D5D6FE7CEF1000000000069F048" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/144373/">v.46(1); 1998 Jul</a></li>
<li class="accid">PMC1873980</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 1998 Jul; 46(1):
49–53.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1046%2Fj.1365-2125.1998.00034.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1046/j.1365-2125.1998.00034.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC1873980</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Different effects of itraconazole on the
pharmacokinetics of fluvastatin and lovastatin</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Kivist%26%23x000f6%3B%20KT%5Bauth%5D">K T
Kivistö</a>, <a href="/pubmed/?term=Kantola%20T%5Bauth%5D">T
Kantola</a>, and <a href="/pubmed/?term=Neuvonen%20PJ%5Bauth%5D">P
J Neuvonen</a></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id693881_ai" style="display:none">
<div class="fm-affl" lang="en">Department of Clinical Pharmacology,
University of Helsinki and Helsinki University Central Hospital,
Helsinki, Finland</div>
<div id="cor1">Correspondence: Kari T. Kivistö, MD, Department of
Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4,
FIN-00290 Helsinki, Finland.</div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id693881_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id693881_an">Article notes
<span>►</span></a> <a href="#" class="pmctoggle" rid=
"id693881_cpl">Copyright and License information
<span>►</span></a></div>
<div class="fm-article-notes fm-panel hide half_rhythm" id=
"id693881_an" style="display:none">
<div class="fm-pubdate half_rhythm">Received 1997 Jul 2; Accepted
1998 Jan 29.</div>
</div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id693881_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 1998 Blackwell Science
Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC1873980/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid351815" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid351815title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">The effects of itraconazole on
the pharmacokinetics of fluvastatin and lovastatin, two inhibitors
of HMG-CoA reductase with different pharmacokinetic properties,
were studied.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last">Two separate randomized,
placebo-controlled, cross-over studies, each involving 10 healthy
volunteers, were carried out. The general design was identical in
both studies. The subjects took either 100 mg itraconazole or
matched placebo orally once daily for 4 days. On day 4, 40 mg
fluvastatin or 40 mg lovastatin was administered orally. Plasma
concentrations of fluvastatin, lovastatin, lovastatin acid,
itraconazole and hydroxyitraconazole were determined up to 24
h.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">Itraconazole had no significant
effect on the <em>C</em><sub>max</sub> (190±124 ng
ml<sup>−1</sup><em>vs</em> 197±189 ng ml<sup>−1</sup> (mean±s.d.))
or total AUC (368±153 ng ml<sup>−1</sup> h <em>vs</em> 324±155 ng
ml<sup>−1</sup> h) of fluvastatin compared with placebo. However,
the <em>t</em><sub>1/2,z</sub> of fluvastatin was slightly
prolonged by itraconazole (2.8±0.49 h <em>vs</em> 2.4±0.51 h;
<em>P</em>&lt;0.05). The <em>C</em><sub>max</sub> of lovastatin was
increased about 15-fold (<em>P</em>&lt;0.01) and the total AUC more
than 15-fold (<em>P</em>&lt;0.01) by itraconazole. Similarly, the
<em>C</em><sub>max</sub> and total AUC of lovastatin acid were
increased about 12-fold (95% CI, 5.3 to 17.7-fold;
<em>P</em>&lt;0.01) and 15-fold (95% CI, 4.6 to 26.2-fold;
<em>P</em>&lt;0.01) by itraconazole, respectively. The
<em>t</em><sub>1/2,z</sub> of lovastatin averaged 3.7±3.8 h and
that of lovastatin acid 4.7±4.0 h during the itraconazole phase;
these variables could not be determined in all subjects during the
placebo phase.</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">Itraconazole, even at a small
dosage of 100 mg daily, greatly elevated plasma concentrations of
lovastatin and its active metabolite, lovastatin acid. Lovastatin
should therefore not be used concomitantly with itraconazole and
other potent CYP3A4 inhibitors, or the dosage of lovastatin should
be greatly reduced while using a CYP3A4 inhibitor. In contrast,
fluvastatin concentrations were not significantly increased by
itraconazole, indicating that fluvastatin has much less potential
than lovastatin for clinically significant interactions with
itraconazole and other CYP3A4 inhibitors.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">fluvastatin, interaction, itraconazole,
lovastatin, pharmacokinetics</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">Fluvastatin and lovastatin are
inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase, the rate-limiting step in cholesterol synthesis, which
are widely used in the treatment of hypercholesterolaemia.
Lovastatin is an inactive lactone pro-drug which is hydrolysed
<em>in vivo</em> to lovastatin acid, a competitive inhibitor of
HMG-CoA reductase [<a href="#b1" rid="b1" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002195">1</a>]. However, the oxidative metabolism of
lovastatin is primarily mediated by CYP3A4 [<a href="#b2" rid="b2"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002197">2</a>]. The pharmacokinetics of fluvastatin
differ considerably from those of lovastatin; fluvastatin is not a
pro-drug and it appears to be metabolized mainly by CYP2C9
[<a href="#b3" rid="b3" class=" bibr popnode">3</a>, <a href="#b4"
rid="b4" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002179">4</a>].</p>
<p id="__p6" class="p p-last">Concomitant use of lovastatin and,
for example, cyclosporine, erythromycin or itraconazole is
associated with a considerably increased risk of skeletal muscle
toxicity, a rare but potentially serious side-effect of HMG-CoA
reductase inhibitors [<a href="#b5" rid="b5" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002187">5</a>–<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002178">8</a>]. The cause of these interactions was at
first unclear, but a recent <em>in vivo</em> study strongly
suggests that they result at least partly from inhibition of the
CYP3A4-mediated metabolism of lovastatin [<a href="#b9" rid="b9"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002196">9</a>]. The aim of the present study was to
characterize the effect of itraconazole on the pharmacokinetics of
fluvastatin and, in particular, to evaluate the hypothesis that
fluvastatin is less liable to interact with CYP3A4 inhibitors such
as itraconazole than lovastatin.</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<div id="__sec7" class="sec sec-first">
<h3>Subjects</h3>
<p id="__p7" class="p p-first-last">Ten healthy volunteers
participated in the fluvastatin study (five women and five men; age
range, 20–25 years; weight range, 54–85 kg) and 10 in the
lovastatin study (two women and eight men; age range, 19–24 years;
weight range, 55–90 kg). All volunteers gave their written informed
consent. They were determined to be healthy by a medical history, a
physical examination and blood chemistry tests (including blood
haemoglobin, serum creatine kinase, creatinine and alanine
aminotransferase) before entering the study. None of them had
continuous medications, with the exception of one and three females
who were using oral contraceptive steroids in the lovastatin and
fluvastatin studies, respectively.</p>
</div>
<div id="__sec8" class="sec">
<h3>Study design</h3>
<p id="__p8" class="p p-first-last">Two separate randomized,
placebo-controlled, cross-over studies with two phases, separated
by a wash-out period of 3 weeks, were carried out. The general
design was identical in both studies. The subjects were given
either 100 mg itraconazole (Sporanox, Janssen, Beerse, Belgium) or
matched placebo orally once daily at 08.00 h for 4 days. On day 4,
40 mg fluvastatin (one Canef 40 mg capsule, Astra Ltd, Kirkkonummi,
Finland) or 40 mg lovastatin (one Mevacor 40 mg tablet, Merck Sharp
&amp; Dohme B.V., Haarlem, Netherlands) was administered orally
with 150 ml water at 09.00 h, i.e. 1 h after the last dose of
itraconazole. The subjects fasted for 1 h before administration of
fluvastatin or lovastatin. A warm standard meal was served 4 h and
a light standard meal 8 h after fluvastatin or lovastatin intake.
The subjects were not allowed to drink grapefruit juice or alcohol
during the study days and the previous 24 h. The study protocol was
approved by the Ethics Committee of the Department of Clinical
Pharmacology, University of Helsinki, and the Finnish National
Agency for Medicines.</p>
</div>
<div id="__sec9" class="sec">
<h3>Blood sampling and determination of plasma drug
concentrations</h3>
<p id="__p9" class="p p-first">On day 4, a forearm vein was
cannulated and timed blood samples were drawn just before
fluvastatin or lovastatin was administered and 0.5, 1, 2, 3, 4, 6,
8, 12 and 24 h later. The blood samples (10 ml each) were taken
into tubes that contained ethylenediaminetetra-acetic acid (EDTA).
Plasma was stored at −40° C until analysis. Plasma concentrations
of lovastatin and lovastatin acid were determined by high
performance liquid chromatography (h.p.l.c.), as previously
described [<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002177">10</a>]. Simvastatin was used as an internal
standard. The limit of quantification was 2.5 ng ml<sup>−1</sup>
for both compounds. The within-day coefficient of variation (CV)
was 4.1% (mean, 9.9 ng ml<sup>−1</sup>, <em>n</em>=10) for
lovastatin and 7.8% (mean, 10.1 ng ml<sup>−1</sup>, <em>n</em>=10)
for lovastatin acid. The between-day CVs were 6.0% (mean, 10.1 ng
ml<sup>−1</sup>, <em>n</em>=4) and 2.7% (mean, 48.1 ng
ml<sup>−1</sup>, <em>n</em>=5) for lovastatin and 8.3% (mean, 9.4
ng ml<sup>−1</sup>, <em>n</em>=4) and 3.0% (mean, 50.6 ng
ml<sup>−1</sup>, <em>n</em>=5) for lovastatin acid.</p>
<p id="__p10">Fluvastatin concentrations were determined by
h.p.l.c. using automated solid phase extraction and fluorescence
detection [<a href="#b11" rid="b11" class=" bibr popnode">11</a>].
The limit of quantification for fluvastatin was 0.4 ng
ml<sup>−1</sup>. The within-day CV for fluvastatin was 4.3% at 0.49
ng ml<sup>−1</sup> (<em>n</em>=6) and 2.4% at 43.6 ng
ml<sup>−1</sup> (<em>n</em>=8). The between-day CV was 2.5% (mean,
21.3 ng ml<sup>−1</sup>, <em>n</em>=8).</p>
<p id="__p11" class="p p-last">To assess the comparability of
plasma itraconazole and hydroxyitraconazole levels between the
lovastatin and fluvastatin studies, plasma itraconazole and
hydroxyitraconazole concentrations were determined in all samples,
i.e. from 1 h after the last itraconazole dose on day 4 up to 25 h.
Itraconazole and hydroxyitraconazole concentrations were determined
by h.p.l.c. as previously described [<a href="#b12" rid="b12"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002194">12</a>]. The limit of quantification was 10 ng
ml<sup>−1</sup> for both compounds. The within-day CV was &lt;10%
for both compounds at relevant concentrations. The between-day CV
was 2.1% (mean, 196 ng ml<sup>−1</sup>, <em>n</em>=10) for
itraconazole and 3.7% (mean, 198 ng ml<sup>−1</sup>, <em>n</em>=10)
for hydroxyitraconazole. At a mean concentration of about 20 ng
ml<sup>−1</sup>, the between-day CV was &lt;10% for both compounds
(<em>n</em>=10).</p>
</div>
<div id="__sec10" class="sec">
<h3>Pharmacokinetics</h3>
<p id="__p12" class="p p-first-last">The pharmacokinetics of
fluvastatin, lovastatin and lovastatin acid were characterized, as
appropriate, by peak concentration in plasma
(<em>C</em><sub>max</sub>), time to <em>C</em><sub>max</sub>
(<em>t</em><sub>max</sub>), area under the plasma
concentration-time curve (AUC) and elimination half-life
(<em>t</em><sub>1/2,z</sub>). The terminal log-linear phase of the
plasma concentration-time curve was identified visually for each
subject. The elimination rate constant (λ<sub>z</sub>) was
determined by a linear regression analysis of the log-linear part
of the plasma concentration-time curve. The
<em>t</em><sub>1/2,z</sub> was calculated from the equation:
<em>t</em><sub>1/2,z</sub>=ln 2/λ<sub>z</sub>. The AUC values were
calculated by the trapezoidal rule, with extrapolation to infinity
by dividing the last measured concentration by λ<sub>z</sub>. The
λ<sub>z</sub> for lovastatin and lovastatin acid could not be
accurately determined in all subjects during the placebo phase due
to low plasma drug concentrations. For itraconazole and
hydroxyitraconazole, the AUC (1,25 h) on day 4 was determined by
the trapezoidal rule.</p>
</div>
<div id="__sec11" class="sec sec-last">
<h3>Statistical analysis</h3>
<p id="__p13" class="p p-first-last">Results are expressed as mean
values±s.d. or, in case of <em>t</em><sub>max</sub>, as median with
range. 95% confidence intervals (CI) were calculated for selected
variables. The pharmacokinetic variables between the two
pretreatments (itraconazole and placebo) were compared with a
paired <em>t</em>-test (two-tailed). The Wilcoxon test was used for
analysis of <em>t</em><sub>max</sub>. The data were analysed with
the statistical program Systat for Windows, version 5.0 (Systat,
Evanston, USA). The level of statistical significance was
<em>P</em>&lt;0.05.</p>
</div>
</div>
<div id="__sec12" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec12title">Results</h2>
<div id="__sec13" class="sec sec-first">
<h3>Fluvastatin</h3>
<p id="__p14" class="p p-first-last">Pretreatment with itraconazole
had no significant effect on the <em>C</em><sub>max</sub> (190±124
ng ml<sup>−1</sup><em>vs</em> 197±189 ng ml<sup>−1</sup>) or total
AUC (368±153 ng ml<sup>−1</sup> h <em>vs</em> 324±155 ng
ml<sup>−1</sup> h) of fluvastatin (<a href=
"/pmc/articles/PMC1873980/table/tbl1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>, <a href=
"/pmc/articles/PMC1873980/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>).
The total AUC of fluvastatin during the itraconazole phase relative
to that during the placebo phase averaged 1.27 (95% CI, 0.89–1.65).
The <em>t</em><sub>1/2,z</sub> of fluvastatin was slightly
prolonged by itraconazole (2.8±0.5 h <em>vs</em> 2.4±0.5 h;
<em>P</em>&lt;0.05).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1873980/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC1873980/bin/bcp0046-0049-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC1873980/bin/bcp0046-0049-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC1873980/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>Plasma concentrations of fluvastatin in 10 healthy
volunteers (mean±s.e. mean) after a 40 mg oral dose, following
pretreatment with 100 mg itraconazole (closed circles) or placebo
(open circles) once daily for 4 days.</span></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC1873980/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC1873980/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC1873980/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC1873980/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>The pharmacokinetic variables of fluvastatin 40 mg
(mean±s.d. or median and range) in 10 subjects (study I) and those
of lovastatin 40 mg in 10 subjects (study II), following
pretreatment with placebo or 100 mg itraconazole once daily for 4
days.</span> <strong>...</strong></div>
</div>
</div>
</div>
<div id="__sec14" class="sec">
<h3>Lovastatin and lovastatin acid</h3>
<p id="__p15" class="p p-first">Itraconazole considerably increased
the plasma concentrations of both lovastatin and lovastatin acid,
compared with placebo (<a href=
"/pmc/articles/PMC1873980/table/tbl1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>, <a href=
"/pmc/articles/PMC1873980/figure/fig02/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob=
"ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>).
The <em>C</em><sub>max</sub> of lovastatin was increased about
15-fold (<em>P</em>&lt;0.01) and the total AUC more than 15-fold
(<em>P</em>&lt;0.01) by itraconazole. The
<em>t</em><sub>1/2,z</sub> of lovastatin averaged 3.7±3.8 h during
the itraconazole phase, but during the placebo phase it could be
determined in only four subjects (mean, 2.6 h) due to the low
plasma lovastatin concentrations.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02"
co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1873980/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02"><img src=
"/pmc/articles/PMC1873980/bin/bcp0046-0049-f2.gif" class=
"small-thumb" alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC1873980/bin/bcp0046-0049-f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig02">
<div><a class="figpopup" href=
"/pmc/articles/PMC1873980/figure/fig02/" target="figure"
rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div>
<!--caption a4-->
<div><span>Plasma concentrations of lovastatin (a) and lovastatin
acid (b) in 10 healthy volunteers (mean±s.e. mean) after a 40 mg
oral dose of lovastatin, following pretreatment with 100 mg
itraconazole (closed circles) or placebo (open circles) once
daily</span> <strong>...</strong></div>
</div>
</div>
<p id="__p16" class="p p-last">The <em>C</em><sub>max</sub> and
total AUC of lovastatin acid were increased about 12-fold (95% CI,
5.3-fold to 17.7-fold; <em>P</em>&lt;0.01) and 15-fold (95% CI,
4.6-fold to 26.2-fold; <em>P</em>&lt;0.01) by itraconazole,
respectively. The <em>t</em><sub>1/2,z</sub> of lovastatin acid was
4.7±4.0 h during the itraconazole phase; in the placebo phase, it
could be determined in only five subjects, averaging 6.1 h.</p>
</div>
<div id="__sec15" class="sec sec-last">
<h3>Itraconazole and hydroxyitraconazole</h3>
<p id="__p17" class="p p-first-last">The mean plasma concentrations
of itraconazole and its active metabolite hydroxyitraconazole on
the day of fluvastatin or lovastatin administration are shown in
<a href="/pmc/articles/PMC1873980/figure/fig03/" target="figure"
class="fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob=
"ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure 3</span></a>.
The AUC (1,25 h) of itraconazole was 1921±849 ng ml<sup>−1</sup> h
in the fluvastatin study and 2018±966 ng ml<sup>−1</sup> h in the
lovastatin study and that of hydroxyitraconazole was 5497±2083 and
5557±2335 ng ml<sup>−1</sup> h, respectively. There was no
significant difference in the AUC (1,25 h) of itraconazole or
hydroxyitraconazole between the two studies.</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03"
co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1873980/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03"><img src=
"/pmc/articles/PMC1873980/bin/bcp0046-0049-f3.gif" class=
"small-thumb" alt="Figure 3" title="Figure 3" src-large=
"/pmc/articles/PMC1873980/bin/bcp0046-0049-f3.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig03">
<div><a class="figpopup" href=
"/pmc/articles/PMC1873980/figure/fig03/" target="figure"
rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div>
<!--caption a4-->
<div><span>Plasma concentrations of itraconazole (open circles,
fluvastatin study; closed circles, lovastatin study) and
hydroxyitraconazole (open triangles, fluvastatin study; closed
triangles, lovastatin study) after intake of 100 mg itraconazole
orally once daily</span> <strong>...</strong></div>
</div>
</div>
</div>
</div>
<div id="__sec16" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec16title">Discussion</h2>
<p id="__p18" class="p p-first">The results of this study
demonstrate that plasma concentrations of the pro-drug lovastatin
and its active metabolite, lovastatin acid, are greatly increased
by a daily dose of 100 mg itraconazole. By contrast, itraconazole
had no significant effect on plasma fluvastatin concentrations.
However, the half-life of fluvastatin was slightly prolonged by
itraconazole, but this should not have any clinical relevance. The
increase in the total AUC of lovastatin acid by itraconazole was,
on an average, 15-fold, but showed marked interindividual
variation. Itraconazole appeared to have a similar effect on the
total AUC of lovastatin; however, this interaction could not be
accurately quantified, since the lovastatin concentrations during
the placebo phase were often below the limit of quantification.</p>
<p id="__p19">These results are in good agreement with the
knowledge of the biotransformation of lovastatin and fluvastatin.
The pro-drug lovastatin is partly hydrolysed to the active
metabolite, lovastatin acid; this metabolic pathway is not
dependent on the CYP enzymes. In contrast, formation of the other
major metabolites of lovastatin is catalysed by CYP enzymes,
primarily by CYP3A4 [<a href="#b2" rid="b2" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002182">2</a>]. Thus, although the hydrolysis of
lovastatin to lovastatin acid is not dependent on CYP3A4,
inhibition of CYP3A4 by itraconazole results in greatly elevated
plasma lovastatin concentrations, leading to a corresponding
increase in lovastatin acid levels. Unlike lovastatin, fluvastatin
seems to be metabolized primarily by CYP2C9; CYP3A4 does not play a
significant role in fluvastatin biotransformation [<a href="#b3"
rid="b3" class=" bibr popnode">3</a>, <a href="#b4" rid="b4" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002190">4</a>].</p>
<p id="__p20">Lovastatin has a low oral bioavailability due to
incomplete absorption and extensive first-pass metabolism [<a href=
"#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002183">13</a>]. Considering that the
<em>C</em><sub>max</sub> and AUC of lovastatin and lovastatin acid
were greatly increased by itraconazole, with only a minor effect on
their <em>t</em><sub>1/2,z</sub>, as well as the fact that
significant quantities of CYP3A4 are present in the gut wall and
liver, it is likely that the interaction between lovastatin and
itraconazole results mainly from inhibition of the CYP3A4-mediated
first-pass metabolism of lovastatin.</p>
<p id="__p21">In a previous study, a 4-day pretreatment with
itraconazole, 200 mg daily, increased the AUC of lovastatin and
lovastatin acid about 20-fold [<a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002186">9</a>]. One aim of the present study was to
evaluate the effect of a lower itraconazole dosage, 100 mg daily,
on lovastatin pharmacokinetics. Although the lower itraconazole
dosage appeared to have a slightly smaller effect on the plasma
levels of lovastatin and lovastatin acid, it also is associated
with a clinically significant risk of interaction with
lovastatin.</p>
<p id="__p22">Considering the marked effect of itraconazole 100 mg
daily on plasma lovastatin and lovastatin acid concentrations as
well as its lack of effect on plasma fluvastatin, it is unlikely
that a clinically significant interaction would occur between
fluvastatin and higher dosages of itraconazole. In a recent study,
AUC values for fluvastatin were about 2-fold higher in
hypercholesterolaemic renal transplant patients receiving
fluvastatin 20 mg day<sup>−1</sup> concomitantly with cyclosporine
than in hypercholesterolaemic patients who had not undergone renal
transplantation and were not receiving cyclosporine [<a href="#b14"
rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002191">14</a>]. However, this difference in the AUC of
fluvastatin observed between the two groups may be related more to
underlying diseases, such as decreased renal function, in the
transplant patients than to cyclosporine therapy. In any event, it
should be noted that apart from inhibiting CYP3A4, cyclosporine and
itraconazole may increase plasma concentrations of HMG-CoA
reductase inhibitors and other drugs by inhibiting P-glycoprotein
mediated drug elimination [<a href="#b15" rid="b15" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002180">15</a>, <a href="#b16" rid="b16" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002188">16</a>].</p>
<p id="__p23">Concomitant administration of the CYP3A4 inhibitors
cyclosporine and erythromycin has been shown to increase the
incidence and severity of the skeletal muscle toxicity of
lovastatin [<a href="#b5" rid="b5" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_130002184">5</a>,
<a href="#b6" rid="b6" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_341070710">6</a>,
<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002192">8</a>]. In addition, a severe case of
rhabdomyolysis occurring in a patient receiving both itraconazole
(200 mg day<sup>−1</sup>) and lovastatin has been reported
[<a href="#b7" rid="b7" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002193">7</a>]. These interactions probably result from
the greatly elevated blood and tissue concentrations of lovastatin
acid; normally, monotherapy with lovastatin is well tolerated due
to the low levels of lovastatin acid.</p>
<p id="__p24">The biotransformation of the pro-drug simvastatin is
similar to that of lovastatin [<a href="#b13" rid="b13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002189">13</a>] and it might therefore be expected that
simvastatin would also interact with itraconazole and other potent
CYP3A4 inhibitors to a clinically significant degree. Indeed,
several recent case reports indicate that concomitant therapy with
simvastatin and itraconazole, cyclosporine or other CYP3A4
inhibitors predisposes to myositis and rhabdomyolysis [<a href=
"#b17" rid="b17" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002185">17</a>–<a href="#b20" rid="b20" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002198">20</a>]. These case-reports conform well with our
recent data which indicate that simvastatin acid concentrations are
greatly increased by itraconazole [<a href="#b21" rid="b21" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_130002181">21</a>].</p>
<p id="__p25" class="p p-last">In conclusion, the results of this
study indicate that itraconazole, even at a dosage of 100 mg daily,
greatly elevates plasma concentrations of lovastatin and its active
metabolite, lovastatin acid. Lovastatin (and simvastatin) should
not be used concomitantly with potent CYP3A4 inhibitors, or the
dosage of these statins should be greatly reduced while using
CYP3A4 inhibitors. By contrast, fluvastatin concentrations were not
significantly increased by itraconazole, indicating that
fluvastatin has much less potential than lovastatin for clinically
significant interactions with itraconazole and other CYP3A4
inhibitors.</p>
</div>
<div id="__ackid656426" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ackid656426title">
Acknowledgments</h2>
<div class="sec">
<p id="__p26">The skilful technical assistance of Mr Jouko Laitila,
Mrs Kerttu Mårtensson, Mrs Lisbet Partanen and Mrs Eija
Mäkinen-Pulli is greatly appreciated. Plasma fluvastatin
concentrations were kindly determined by Astra Hässle Ltd. This
study was supported by a grant from the Helsinki University Central
Hospital Research Fund.</p>
</div>
</div>
<div id="__ref-listid656435" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid656435title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"citation">Duggan DE, Chen IW, Bayne WF, et al. The physiological
disposition of lovastatin. <span><span class="ref-journal">Drug
Metab Dispos.</span> 1989;<span class=
"ref-vol">17</span>:166–173.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/2565206" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"citation">Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas
KP. Biotransformation of lovastatin. IV. Identification of
cytochrome P450, 3A proteins as the major enzymes responsible for
the oxidative metabolism of lovastatin in rat and human liver
microsomes. <span><span class="ref-journal">Arch Biochem
Biophys.</span> 1991;<span class=
"ref-vol">290</span>:355–361.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1929403" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"citation">Transon C, Leemann T, Dayer P. Selective <em>in
vitro</em> P450 inhibition profile by fluvastatin indicates its
potential <em>in vivo</em> drug interactions. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 1993;<span class=
"ref-vol">53</span>:188.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"citation">Transon C, Leemann T, Vogt N, Dayer P. <em>In vivo</em>
inhibition profile of cytochrome P450TB (CYP2C9) by (±)
-fluvastatin. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 1995;<span class="ref-vol">58</span>:412–417.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/7586933" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"citation">Norman DJ, Illingworth DR, Munson J, Hosenpud J.
Myolysis and acute renal failure in a heart-transplant patient
receiving lovastatin. <span><span class="ref-journal">N Engl J
Med.</span> 1988;<span class="ref-vol">318</span>:46–47.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/3275891" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"citation">Tobert JA. Efficacy and long-term adverse effect pattern
of lovastatin. <span><span class="ref-journal">Am J Cardiol.</span>
1988;<span class="ref-vol">62</span>:28–34.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/3055921" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"citation">Lees RS, Lees AM. Rhabdomyolysis from the
coadministration of lovastatin and the antifungal agent
itraconazole. <span><span class="ref-journal">N Engl J Med.</span>
1995;<span class="ref-vol">333</span>:664–665.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7637734" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"citation">Marinella MA. More on lovastatin. <span><span class=
"ref-journal">West J Med.</span> 1995;<span class=
"ref-vol">162</span>:176–177.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1022662/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/7725700" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"citation">Neuvonen PJ, Jalava K-M. Itraconazole drastically
increases plasma concentrations of lovastatin and lovastatin acid.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
1996;<span class="ref-vol">60</span>:54–61.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8689812" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"citation">Stubbs RJ, Schwartz M, Bayne WF. Determination of
mevinolin and mevinolinic acid in plasma and bile by reversed-phase
high-performance liquid chromatography. <span><span class=
"ref-journal">J Chromatogr.</span> 1986;<span class=
"ref-vol">383</span>:438–443.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/3644824" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"citation">Toreson H, Eriksson B-M. Liquid chromatographic
determination of fluvastatin and its enantiomers in blood plasma by
automated solid-phase extraction. <span><span class=
"ref-journal">Chromatographia.</span> 1997;<span class=
"ref-vol">45</span>:29–34.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"citation">Allenmark S, Edebo A, Lindgren K. Determination of
itraconazole in serum with high-performance liquid chromatography
and fluorescence detection. <span><span class="ref-journal">J
Chromatogr.</span> 1990;<span class=
"ref-vol">532</span>:203–206.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1964163" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"citation">Lennernäs H, Fager G. Pharmacodynamics and
pharmacokinetics of the HMG-CoA reductase inhibitors.
<span><span class="ref-journal">Clin Pharmacokinet.</span>
1997;<span class="ref-vol">32</span>:403–425.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9160173" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"citation">Goldberg R, Roth D. Evaluation of fluvastatin in the
treatment of hypercholesterolemia in renal transplant recipients
taking cyclosporine. <span><span class=
"ref-journal">Transplantation.</span> 1996;<span class=
"ref-vol">62</span>:1559–1564.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8970607" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"citation">Kivistö KT, Kroemer HK, Eichelbaum M. The role of human
cytochrome P450 enzymes in the metabolism of anticancer agents:
implications for drug interactions. <span><span class=
"ref-journal">Br J Clin Pharmacol.</span> 1995;<span class=
"ref-vol">40</span>:523–530.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1365206/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/8703657" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"citation">Bertz RJ, Granneman GR. Use of <em>in vitro</em> and
<em>in vivo</em> data to estimate the likelihood of metabolic
pharmacokinetic interactions. <span><span class="ref-journal">Clin
Pharmacokinet.</span> 1997;<span class=
"ref-vol">32</span>:210–258.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9084960" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"citation">Meier C, Stey C, Brack T, Maggiorini M, Risti B,
Krahenbuhl S. Rhabdomyolysis in patients treated with simvastatin
and cyclosporin: role of the hepatic cytochrome P450 enzyme system
activity. <span><span class="ref-journal">Schweiz Med
Wochenschr.</span> 1995;<span class=
"ref-vol">125</span>:1342–1346.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7624744" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b18">18. <span class=
"citation">Horn M. Coadministration of itraconazole with
hypolipidemic agents may induce rhabdomyolysis in healthy
individuals. <span><span class="ref-journal">Arch Dermatol.</span>
1996;<span class="ref-vol">132</span>:1254.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8859048" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b19">19. <span class=
"citation">Segaert MF, De Soete C, Vandewiele I, Verbanck J.
Drug-interaction-induced rhabdomyolysis. <span><span class=
"ref-journal">Nephrol Dial Transplant.</span> 1996;<span class=
"ref-vol">11</span>:1846–1847.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8918636" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b20">20. <span class=
"citation">Jacobson RH, Wang P, Glueck CJ. Myositis and
rhabdomyolysis associated with concurrent use of simvastatin and
nefazodone. <span><span class="ref-journal">JAMA.</span>
1997;<span class="ref-vol">277</span>:296–297.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9002485" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b21">21. <span class=
"citation">Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not
pravastatin is very susceptible to interaction with the CYP3A4
inhibitor itraconazole. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 1998;<span class=
"ref-vol">63</span>:332–341.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9542477" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1873980&amp;issue-id=144373&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC1873980/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC1873980/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC1873980/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC1873980/pdf/bcp0046-0049.pdf">PDF
(92K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC1873980" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1873980%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1873980%2F&amp;text=Different%20effects%20of%20itraconazole%20on%20the%20pharmacokinetics%20of%20fluvastatin%20and%20lovastatin">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1873980%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="9690949" data-aiid="1873980"
data-aid="1873980" data-iid="144373" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC1873980" data-md5=
"4bc9ae33a1c4aa68764931f8ad1ad5b3"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:11-04:00&amp;Host=ptpmc201">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1873980/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FB6D5D6FE7D821_0105SID /projects/PMC/PMCViewer@4.35 ptpmc201 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
